title: Activin receptor-like kinases: a diverse family playing an important role in cancer.
abstract: The role and function of the members of the TGFβ superfamily has been a substantial area of research focus for the last several decades. During that time, it has become apparent that aberrations in TGFβ family signaling, whether through the BMP, Activin, or TGFβ arms of the pathway, can result in tumorigenesis or contribute to its progression. Downstream signaling regulates cellular growth under normal physiological conditions yet induces diverse processes during carcinogenesis, ranging from epithelial- to-mesenchymal transition to cell migration and invasion to angiogenesis. Due to these observations, the question has been raised how to utilize and target components of these signaling pathways in cancer therapy. Given that these cascades include both ligands and receptors, there are multiple levels at which to interfere. Activin receptor-like kinases (ALKs) are a group of seven type I receptors responsible for TGFβ family signal transduction and are utilized by many ligands within the superfamily. The challenge lies in specifically targeting the often-overlapping functional effects of BMP, Activin, or TGFβ signaling during cancer progression. This review focuses on the characteristic function of the individual receptors within each subfamily and their recognized roles in cancer. We next explore the clinical utility of therapeutically targeting ALKs as some have shown partial responses in Phase I clinical trials but disappointing outcomes when used in Phase II studies. Finally, we discuss the challenges and future directions of this body of work.
authors.affiliation: Department of Cancer Biology, Vanderbilt University Nashville, TN, USA.
authors.forename: Holli A
authors.initials: HA
authors.lastname: Loomans
authors.affiliation: Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida Orlando, FL, USA.
authors.forename: Claudia D
authors.initials: CD
authors.lastname: Andl
keywords: Activin; BMP; TGFβ; targeted therapy